• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer.

作者信息

Iwamoto Hiroaki, Izumi Kouji, Mizokami Atsushi

机构信息

Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

出版信息

Transl Androl Urol. 2024 Jul 31;13(7):1324-1326. doi: 10.21037/tau-23-669. Epub 2024 Jun 27.

DOI:10.21037/tau-23-669
PMID:39100828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11291412/
Abstract
摘要

相似文献

1
Feasibility of androgen-deprivation and radiation therapy with docetaxel for localized high-risk prostate cancer.雄激素剥夺联合多西他赛放疗用于局限性高危前列腺癌的可行性
Transl Androl Urol. 2024 Jul 31;13(7):1324-1326. doi: 10.21037/tau-23-669. Epub 2024 Jun 27.
2
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.雄激素剥夺治疗联合或不联合多西他赛放疗用于局限性高危前列腺癌：NRG 肿瘤学 RTOG 0521 试验的长期随访结果。
Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Epub 2023 May 12.
3
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.高风险前列腺癌同期每周多西他赛、高强度调强放疗（IMRT）和雄激素剥夺治疗（ADT）的 I 期研究。
BJU Int. 2012 Dec;110(11 Pt B):E721-6. doi: 10.1111/j.1464-410X.2012.11536.x. Epub 2012 Sep 27.
4
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.高风险局限性前列腺癌患者放疗联合或不联合同期每周多西他赛进行 3 年雄激素剥夺治疗的 2 期随机研究。
Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):344-352. doi: 10.1016/j.ijrobp.2018.10.005. Epub 2018 Oct 12.
5
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.ERG表达可预测多西他赛联合雄激素剥夺疗法在局限性和转移性激素敏感性前列腺癌中的获益：两项GETUG 3期试验分析
Eur Urol Oncol. 2025 Apr;8(2):296-305. doi: 10.1016/j.euo.2024.06.015. Epub 2024 Jul 20.
6
Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial.多中心Ⅱ期临床试验：同步及辅助多西他赛联合三维适形放疗加雄激素剥夺治疗高危前列腺癌：初步结果。
Radiother Oncol. 2010 Nov;97(2):312-7. doi: 10.1016/j.radonc.2010.08.012. Epub 2010 Sep 16.
7
Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial.非转移性低危前列腺癌的放化疗联合或不联合多西他赛治疗：一项前瞻性随机试验。
J Clin Oncol. 2021 Sep 10;39(26):2938-2947. doi: 10.1200/JCO.21.00596. Epub 2021 Jul 1.
8
Rupture of liver metastasis in high-volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy.接受雄激素剥夺疗法联合多西他赛一线化疗的高负荷转移性前列腺癌患者发生肝转移破裂。
IJU Case Rep. 2022 Jul 27;5(6):451-454. doi: 10.1002/iju5.12512. eCollection 2022 Nov.
9
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.雄激素剥夺疗法联合多西他赛和雌莫司汀与单独雄激素剥夺疗法治疗高危局限性前列腺癌（GETUG 12）：一项 3 期随机对照临床试验。
Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.
10
Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer.早期多西他赛与雄激素剥夺疗法治疗转移性激素敏感性前列腺癌
Rev Recent Clin Trials. 2016;11(4):317-323. doi: 10.2174/1574887111666160719145456.

本文引用的文献

1
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.雄激素剥夺治疗联合或不联合多西他赛放疗用于局限性高危前列腺癌：NRG 肿瘤学 RTOG 0521 试验的长期随访结果。
Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Epub 2023 May 12.
2
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙联合泼尼松或联合恩扎卢胺治疗开始去势治疗的转移性前列腺癌患者：STAMPEDE 平台方案两项随机 3 期试验的最终结果。
Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.
3
Prostate cancer-what about oligometastatic disease and stereotactic ablative radiotherapy?-a narrative review.前列腺癌——寡转移疾病和立体定向消融放疗如何？——一篇叙述性综述。
Ann Palliat Med. 2023 May;12(3):646-652. doi: 10.21037/apm-22-828. Epub 2023 Mar 2.
4
Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer.血清CCL2是非转移性去势敏感性前列腺癌的预后生物标志物。
Biomedicines. 2022 Sep 22;10(10):2369. doi: 10.3390/biomedicines10102369.
5
Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naïve Prostate Cancer in Japanese Men.日本男性转移性激素初治前列腺癌总生存预后模型的开发
Cancers (Basel). 2022 Oct 2;14(19):4822. doi: 10.3390/cancers14194822.
6
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.雄激素受体信号靶向治疗和紫杉烷化疗诱导去势抵抗性前列腺癌内脏转移。
Prostate. 2021 Jan;81(1):72-80. doi: 10.1002/pros.24082. Epub 2020 Oct 13.
7
An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer.转移性前列腺癌预后和预测性血清生物标志物的最新进展
Diagnostics (Basel). 2020 Jul 31;10(8):549. doi: 10.3390/diagnostics10080549.
8
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.多西他赛联合激素治疗在低负担和高负担转移性激素敏感前列腺癌中的应用：来自 STAMPEDE 试验的长期生存结果。
Ann Oncol. 2019 Dec 1;30(12):1992-2003. doi: 10.1093/annonc/mdz396.
9
Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.联合使用PHI和微小RNA作为前列腺癌诊断和预后的生物标志物
Clin Lab. 2019 Jul 1;65(7). doi: 10.7754/Clin.Lab.2019.181213.
10
Targeting lactate dehydrogenase‑A promotes docetaxel‑induced cytotoxicity predominantly in castration‑resistant prostate cancer cells.靶向乳酸脱氢酶 A 可增强多西他赛诱导的细胞毒性，主要针对去势抵抗性前列腺癌细胞。
Oncol Rep. 2019 Jul;42(1):224-230. doi: 10.3892/or.2019.7171. Epub 2019 May 24.